Cite

    Lavacca, A. et al. (2020). Early effects of first‐line treatment with anti‐interleukin‐6 receptor antibody tocilizumab for chronic active antibody‐mediated rejection in kidney transplantation. Clinical transplantation. 34 (8), p. n/a. [Online].